Outcomes Research, The Cleveland Clinic, Cleveland, Ohio, USA.
BMC Anesthesiol. 2009 Feb 3;9:1. doi: 10.1186/1471-2253-9-1.
Even the best cancer surgery is usually associated with minimal residual disease. Whether these remaining malignant cells develop into clinical recurrence is at least partially determined by adequacy of host defense, especially natural killer cell function. Anesthetics impair immune defenses to varying degrees, but nitrous oxide appears to be especially problematic. We therefore tested the hypothesis that colorectal-cancer recurrence risk is augmented by nitrous oxide administration during colorectal surgery.
We conducted a 4- to 8-year follow-up of 204 patients with colorectal cancer who were randomly assigned to 65% nitrous oxide (n = 97) or nitrogen (n = 107), balanced with isoflurane and remifentanil. The primary outcome was the time to cancer recurrence. Our primary analysis was a multivariable Cox-proportional-hazards regression model that included relevant baseline variables. In addition to treatment group, the model considered patient age, tumor grade, dissemination, adjacent organ invasion, vessel invasion, and the number of nodes involved. The study had 80% power to detect a 56% or greater reduction in recurrence rates (i.e., hazard ratio of 0.44 or less) at the 0.05 significance level.
After adjusting for significant baseline covariables, risk of recurrence did not differ significantly for nitrous oxide and nitrogen, with a hazard ratio estimate (95% CI) of 1.10 (0.66, 1.83), P = 0.72. No two-way interactions with the treatment were statistically significant.
Colorectal-cancer recurrence risks were not greatly different in patients who were randomly assigned to 65% nitrous oxide or nitrogen during surgery. Our results may not support avoiding nitrous oxide use to prevent recurrence of colorectal cancer.
The risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.
Current Controlled Clinical Trials NCT00781352 http://www.clinicaltrials.gov.
即使是最好的癌症手术,通常也会伴有微量残留疾病。这些残留的恶性细胞是否会发展成临床复发,至少部分取决于宿主防御的充分性,特别是自然杀伤细胞的功能。麻醉剂会在不同程度上损害免疫防御,但一氧化二氮似乎尤其成问题。因此,我们测试了这样一个假设,即在结直肠手术期间使用一氧化二氮会增加结直肠癌复发的风险。
我们对 204 例结直肠癌患者进行了 4 至 8 年的随访,这些患者被随机分配到 65%的一氧化二氮(n=97)或氮气(n=107)组,两组均与异氟烷和瑞芬太尼平衡。主要结局是癌症复发的时间。我们的主要分析是一个多变量 Cox 比例风险回归模型,包括相关的基线变量。除了治疗组外,该模型还考虑了患者年龄、肿瘤分级、扩散、邻近器官侵犯、血管侵犯和涉及的淋巴结数量。该研究有 80%的功效,可以在 0.05 的显著性水平下检测到复发率降低 56%或更高(即危险比为 0.44 或更低)。
在调整了显著的基线协变量后,一氧化二氮和氮气组的复发风险没有显著差异,危险比估计值(95%CI)为 1.10(0.66,1.83),P=0.72。治疗组之间没有统计学意义的双向相互作用。
在接受手术的患者中,随机分配到 65%的一氧化二氮或氮气组的患者,其结直肠癌复发风险没有显著差异。我们的结果可能不支持为了预防结直肠癌的复发而避免使用一氧化二氮。
在接受结直肠手术的患者中,随机分配到 65%的一氧化二氮或氮气组的患者,其结直肠癌复发的风险相似。
当前对照临床试验 NCT00781352 网址:http://www.clinicaltrials.gov。